

COMPARATIVE STUDIES ON THE EFFECTS OF ZIDOVUDINE, NEVIRAPINE, LAMIVUDINE AND BIOCLEAR II ON FEMALE HIV/AIDS CASES IN NIGERIA

INTRODUCTION

This statement based on a reference from 2003 is outdated and should be checked against the 2014 UNAIDS data

The epidemic seems not to be declining but shows pockets of slowing down or stabilizing in different parts of the world (UNAIDS, 2003).

Antiretroviral drugs classification to be update (Reference from 1997)

The orthodox antiretroviral drugs can be categorised as follows: The reverse transcriptase inhibitors, protease inhibitors and fusion 41 inhibitors (Ficshl et al., 1997).

MATERIALS AND METHODS

Recruitment of study population

- Authors should join the ethics committee approval (Why put patients in need of antiretroviral TREATMENT under a treatment not yet validated ?)
- Authors have to follow WHO Guidelines for good clinical practice (GCP) for trials on pharmaceutical products
- Specify the method of calculating the sample size of the study population

The selection criteria include, prior exposure to antiretroviral drugs (Multiple therapy), for not less than one year (See table 1 patients B and D have ½ year drug exposure)

Viral Antigen detection

- Determine and Unigold tests are used for HIV antibodies detection not viral Antigen detection so change the title (HIV Antibodies detection)
- Authors must precise HIV types (HIV1 or HIV2?)

Viral load determination

- Is it HIV1 viral load determination or HIV2 viral load determination? So precise HIV types

Authors have to mention Statistical analysis methods?

RESULTS

- No titles for Tables 1 and 1a , Authors must melt Tables 1, 1a and 1b

DISCUSSION

REFERENCES

- The reference list is poor please complete with rescent references
- See reference Krieke, 2007 is not listed